The use of andriol in treatment of androgen deficiency in transsexual women.
In search of a non-invasive, long-term acting form of androgen to be used in female-to-male transsexuals, testosterone undecanoate (Andriol, Organon) was investigated from clinical and laboratory points of view. The therapy resulted in a significant elevation of androgens with a considerable increase of the free testosterone fraction, desired virilization and somatic changes to a masculine phenotype. Testosterone undecanoate provides sufficiently high androgen levels without significant influence on the hypothalamo-pituitary-gonadal axis. The treatment impaired neither liver function nor glucose tolerance. It is concluded that this drug is suitable for hormonal preparation before the reconstructive therapy to males.
R
R
Hampl
L
L
Stárka
J
J
Heresová
I
I
Sípová
Z
Z
Pobisová
J
J
Marek
D000328:Adult; D000728:Androgens / Q000172:deficiency*; D005260:Female; D012739:Gonadal Steroid Hormones / Q000032:analysis; D006801:Humans; D007700:Kinetics; D013739:Testosterone / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D014189:Transsexualism / Q000188:drug therapy* / Q000378:metabolism
D000728:Androgens; D012739:Gonadal Steroid Hormones; D013739:Testosterone; C010792:testosterone undecanoate